These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 6734448

  • 1. [Effect of low-molecular heparin on blood coagulation].
    Harenberg J, de Vries JX, Weber E, Zimmermann R.
    Dtsch Med Wochenschr; 1984 Jun 15; 109(24):951-4. PubMed ID: 6734448
    [Abstract] [Full Text] [Related]

  • 2. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1989 Jun 30; 61(3):357-62. PubMed ID: 2552604
    [Abstract] [Full Text] [Related]

  • 3. Effect of low molecular weight heparin on coagulation parameters and bleeding time in healthy volunteers.
    Warning A, Nies D, Wolf H, Welzel D.
    Arzneimittelforschung; 1987 Jul 30; 37(7):847-9. PubMed ID: 2823841
    [Abstract] [Full Text] [Related]

  • 4. [Low molecular weight heparins].
    Kher A, Bara L, Samama M.
    Pathol Biol (Paris); 1986 Jan 30; 34(1):61-9. PubMed ID: 3517772
    [Abstract] [Full Text] [Related]

  • 5. [Preliminary study of the use of low-molecular weight heparin to prevent thrombotic risk].
    Delahousse B, Gruel Y, Moalic P, Foloppe P, Leclerc MH, Guerois C, Fimbel B, Leroy J.
    J Mal Vasc; 1986 Jan 30; 11(4):330-7. PubMed ID: 3805895
    [Abstract] [Full Text] [Related]

  • 6. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. I. Effects of heparin fractions.
    Schmitz-Huebner U, Balleisen L, Asbeck F, van de Loo J.
    Thromb Haemost; 1981 Oct 30; 46(3):612-6. PubMed ID: 7031982
    [Abstract] [Full Text] [Related]

  • 7. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F.
    Thromb Haemost; 1988 Jun 16; 59(3):388-91. PubMed ID: 2847348
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Jun 16; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]

  • 10. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR, Mourão PA.
    Thromb Haemost; 2008 Mar 16; 99(3):531-8. PubMed ID: 18327401
    [Abstract] [Full Text] [Related]

  • 11. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. II. Effects of a heparin analogue.
    Schmitz-Huebner U, Asbeck F, van de Loo J.
    Thromb Haemost; 1981 Oct 16; 46(3):617-20. PubMed ID: 6797091
    [Abstract] [Full Text] [Related]

  • 12. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD, Oliveira C, Bruges M, Gusmão L, Santana A, Ponce P, Simões J, Freire I, Crespo F, da Silva AN.
    Acta Med Port; 1992 Feb 16; 5(2):65-70. PubMed ID: 1317657
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K.
    Blood Coagul Fibrinolysis; 1993 Dec 16; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [Abstract] [Full Text] [Related]

  • 16. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
    Lane DA, Ireland H, Flynn A, Anastassiades E, Curtis JR.
    Nephrol Dial Transplant; 1986 Dec 16; 1(3):179-87. PubMed ID: 2955253
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Therapeutic indications of low molecular weight heparins].
    Samama MM, Michaut-Paterno F.
    Arch Mal Coeur Vaiss; 1991 Nov 16; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [Abstract] [Full Text] [Related]

  • 19. A comparison of pentosan polysulphate and heparin. II: Effects of subcutaneous injection.
    Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP.
    Thromb Haemost; 1982 Apr 30; 47(2):109-13. PubMed ID: 6179183
    [Abstract] [Full Text] [Related]

  • 20. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May 30; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.